Metabolic syndrome in type 2 diabetes: comparative prevalence according to two sets of diagnostic criteria in sub-Saharan Africans

Diabetology & Metabolic Syndrome

Christophe Nouedoui¹  Cathérine FT Djouogo⁴  Eugene Sobngwi²  Serge N Limen⁴  Andre P Kengne³ 

[1] General Hospital Yaounde and Faculty of medicine and biomedical sciences university of Yaounde 1-Cameroon, Yaounde, Cameroon;Institute of Health and Society; The Medical School, University of Newcastle Upon Tyne, Newcastle, UK;NCRP for Cardiovascular and metabolic diseases, South African Medical research Council & University of Cape Town, Cape Town, South Africa;Higher Institute of Health Sciences, Bangangte, Cameroon

关键词: Sub-Saharan Africa;    Cameroon;    Concordance;    Prevalence;    Diabetes mellitus;    Metabolic syndrome;   

Others  :  815055
DOI  :  10.1186/1758-5996-4-22

 received in 2012-01-31, accepted in 2012-05-31,  发布年份 2012

【 摘 要 】

Background

Available definition criteria for metabolic syndrome (MS) have similarities and inconsistencies. The aim of this study was to determine the prevalence of MS in a group of Cameroonians with type 2 diabetes, according to the International Diabetes Federation (IDF) and the National Cholesterol Education Programme Adult Treatment Panel III (NCEP-ATP III) criteria, and to assess the concordance between both criteria, and the implications of combining them.

Methods

We collected clinical and biochemical data for 308 patients with type 2 diabetes (men 157) at the National Obesity Center of the Yaounde Central Hospital, Cameroon. Concordance was assessed with the use of the Kappa statistic.

Results

Mean age (standard deviation) was 55.8 (10.5) years and the median duration of diagnosed diabetes (25^th–75^th percentiles) was 3 years (0.5–5.0), similarly among men and women. The prevalence of MS was 71.7% according to the IDF criteria and 60.4% according to NCEP-ATP III criteria. The prevalence was significantly higher in women than in men independently of the criteria used (both p < 0.001). Overall concordance between both definitions was low to average 0.51 (95% confidence interval: 0.41–0.61). Combining the two sets of criteria marginally improved the yield beyond that provided by the IDF criteria alone in men, but not in the overall population and in women.

Conclusions

The IDF and NCEP-ATP III criteria do not always diagnose the same group of diabetic individuals with MS and combining them merely increases the yield beyond that provided by the IDF definition alone. This study highlights the importance of having a single unifying definition for MS in our setting.

【 授权许可】

   
2012 Kengne et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Zimmet P, McCarty DJ, de Courten MP: The global epidemiology of non-insulin-dependent diabetes mellitus and the metabolic syndrome. J Diabetes Complications 1997, 11:60-68.
• [2]Marchesini G: BM, Bianchi G, Tomassetti S, Bugianesi E, Lenzi M, McCullough AJ, Natale S, Forlani G. Melchionda N: Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001, 50:1844-1850.
• [3]Reaven GM: Role of insulin resistance in human disease. Diabetes 1988, 37:1595-1607.
• [4]International Diabetes Federation: The IDF consensus worldwide definition of the metabolic syndrome. 2005. Available at http://www.idf.org/webdata/docs/Metabolic_syndrome_definition.pdf webcite. Accessed on 28.02.2012
• [5]Paresh D, Ahmad A, Ajay C, Priya M, Rajesh G: Metabolic Syndrome :A Comprehensive Perspective Based on Interactions Between Obesity, Diabetes, and Inflammation. Circulation 2005, 111:1448-1454.
• [6]Lorenzo C, Okoloise M, Williams K, Stern MP, Haffner SM: The Metabolic Syndrome as Predictor of Type 2 Diabetes. Diabetes Care 2003, 26:3153-3159.
• [7]Alberti KG, Zimmet P: Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998, 15:539-553.
• [8]Balkau B, Charles MA: Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabet Med 1999, 16:442-443.
• [9]Expert Panel on Detection: Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive Summary of the third national cholesterol education program expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Panel Treatment III). Jama 2001, 285:2486-2497.
• [10]International Diabetes Federation (ed.): Diabetes Atlas. 5th edition. Brussels; 2011.
• [11]Okafor CI: Metabolic syndrome in Africa: Current trends. Indian J Endocrinol Metab 2012, 16:56-66.
• [12]Faergeman O: The atherosclerosis epidemic: methodology, nosology, and clinical practice. Am J Cardiol 2001, 88:4E-7E.
• [13]Fezeu L, Balkau B, Kengne AP, Sobngwi E, Mbanya JC: Metabolic syndrome in a sub-Saharan African setting: central obesity may be the key determinant. Atherosclerosis 2007, 193:70-76.
• [14]Alebiosu CO, Odusan BO: Metabolic syndrome in subjects with type-2 diabetes mellitus. J Natl Med Assoc 2004, 96:817-821.
• [15]Adediran OS, Edo AE, Jimoh AK, Ohwovoriole AE: Prevalence of the Metabolic Syndrome among Nigerians with Type 2 Diabetes. Diabetes Int 2007, 15:13-14.
• [16]Isezuo SA, Ezunu E: Demographic and clinical correlates of metabolic syndrome in Native African type-2 diabetic patients. J Natl Med Assoc 2005, 97:557-563.
• [17]Isezuo SA: Is high density lipoprotein cholesterol useful in diagnosis of metabolic syndrome in native Africans with type 2 diabetes? Ethn Dis 2005, 15:6-10.
• [18]Puepet FH, Uloko A, Akogu IY, Aniekwensi E: Prevalence of the metabolic syndrome among patients with type 2 diabetes mellitus in urban North-central Nigeria. Afr J Endocrinol Metab 2009, 8:10-12.
• [19]Unadike BC, Akpan NA, Peters EJ, Essien IO, Essien OE: Prevalence of the metabolic syndrome among patients with type 2 diabetes mellitus in Uyo, Nigeria. Afr J Endocrinol Metab 2009, 8:7-9.
• [20]Onyekwere CA, Ogbera AO, Balogun BO: Non-alcoholic fatty liver disease and the metabolic syndrome in an urban hospital serving an African community. Ann Hepatol 2011, 10:119-124.
• [21]Ogbera AO, Azenabor AO: Hyperuricaemia and the metabolic syndrome in type 2 DM. Diabetol Metab Syndr 2010, 2:24. BioMed Central Full Text
• [22]Ogbera A, Fasanmade O, Kalra S: Menopausal symptoms and the metabolic syndrome in Nigerian women with type 2 diabetes mellitus. Climacteric 2011, 14:75-82.
• [23]Ogbera AO: Prevalence and gender distribution of the metabolic syndrome. Diabetol Metab Syndr 2010, 2:1. BioMed Central Full Text
• [24]Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, James WP, Loria CM, Smith SC: Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009, 120:1640-1645.
• [25]Makuyana D, Gomo Z, Munyombwe T, Matenga JA, Hakim JG: Metabolic syndrome disorders in urban black Zimbabweans with type 2 Diabetes mellitus. Cent Afr J Med 2004, 50:24-29.
• [26]Kelliny C, William J, Riesen W, Paccaud F, Bovet P: Metabolic syndrome according to different definitions in a rapidly developing country of the African region. Cardiovasc Diabetol 2008, 7:27. BioMed Central Full Text
• [27]Kalk WJ, Joffe BI: The metabolic syndrome, insulin resistance, and its surrogates in African and white subjects with type 2 diabetes in South Africa. Metab Syndr Relat Disord 2008, 6:247-255.
• [28]Monami M, Marchionni N, Masotti G, Mannucci E: IDF and ATP-III definitions of metabolic syndrome in the prediction of all-cause mortality in type 2 diabetic patients. Diabetes Obes Metab 2007, 9:350-353.
• [29]Luk AO, Ma RC, So WY, Yang XL, Kong AP, Ozaki R, Ko GT, Chow CC, Cockram CS, Chan JC, et al.: The NCEP-ATPIII but not the IDF criteria for the metabolic syndrome identify Type 2 diabetic patients at increased risk of chronic kidney disease. Diabet Med 2008, 25:1419-1425.
• [30]Janghorbani M, Amini M: Metabolic syndrome in type 2 diabetes mellitus in isfahan, iran: prevalence and risk factors. Metab Syndr Relat Disord 2007, 5:243-254.
• [31]Motala AA, Esterhuizen T, Pirie FJ, Omar MA: The prevalence of metabolic syndrome and determination of the optimal waist circumference cutoff points in a rural South african community. Diabetes Care 2011, 34:1032-1037.
• [32]Kengne AP, Njamnshi AK, Mbanya JC: Cardiovascular Risk Reduction in Diabetes in Sub-Saharan-Africa: What should the Priorities be in the Absence of Global Risk Evaluation Tools? Clinical Medicine: Cardiology 2008, 2:25-31.
• [33]Kengne AP, Djouogo CF, Dehayem MY, Fezeu L, Sobngwi E, Lekoubou A, Mbanya JC: Admission trends over 8 years for diabetic foot ulceration in a specialized diabetes unit in cameroon. Int J Low Extrem Wounds 2009, 8:180-186.
• [34]Reichenheim ME: Sample size for the kappa-statistic of interrater agreement. Stata Technical Bulletin 2000, 58:41-45.
• [35]Fleiss JL, Cohen J, Everitt BS: Large sample standard errors for kappa and weighted kappa. Psychol Bull 1969, 72:323-327.
• [36]Fleiss JL: Statistical Methods for Rates and Proportions. 2nd edition. Wiley & Sons, New York; 1981.
• [37]Cantor AB: Sample size calculations for Cohen’s k. Psychological Methods 1996, 1:150-153.